Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing <i>Enterobacterales</i>
Juan Carlos Vázquez-Ucha, Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez, Marina Oviaño, Laura Álvarez-Fraga, Isaac Alonso-García, Jorge Arca-Suárez, German Bou, Alejandro Beceiro
Abstract
1/≥128 mg/L), with MICs ≥16 mg/L for 49 MBL producers, 40 OXA-48 producers (13 with amino acid changes in OmpK35/36, 4 in PBPs and 11 in RamR) and 25 KPC producers (most with an insertion in OmpK36). These results confirm the therapeutic potential of the new β-lactamase inhibitors, shedding light on the activity of cefepime and BLIs against CPE and resistance mechanisms. The cefepime/zidebactam and cefepime/taniborbactam combinations are particularly highlighted as promising alternatives to penicillin-based inhibitors for the treatment of CPE.
Topics & Concepts
CefepimeBiologyMicrobiologyEnzymeBacteriaDrug resistanceGenomeAcquired resistancePharmacologyAntibacterial agentAntibiotic resistanceAntibioticsEnzyme assayCephalosporinAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyInfections and bacterial resistance